Quantcast

Latest Smith, Kline & French Stories

2009-01-29 15:31:00

PHILADELPHIA, Jan. 29 /PRNewswire-FirstCall/ -- On Thursday, February 5th, GlaxoSmithKline plc (NYSE: GSK) will announce its year end financial results for the year ended December 31, 2008. The announcement is scheduled for release to the London Stock Exchange at approximately 7:00 AM Eastern Standard Time (EST). At 9:00 AM EST Andrew Witty, Chief Executive Officer, and Julian Heslop, Chief Financial Officer will hold a briefing meeting for analysts and investors. The meeting is available...

2009-01-07 07:50:00

LONDON, Jan. 7 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) announced today the successful completion of the tender offer by its wholly-owned subsidiary Gemstone Acquisition Corporation for shares of common stock of Genelabs Technologies, Inc. (Nasdaq: GNLB). The tender offer expired at 12:00 midnight, New York City time, on Tuesday, January 6, 2009. The depositary for the tender offer has advised GSK that shareholders of Genelabs have tendered and not withdrawn a total of...

2008-12-30 07:50:00

LONDON, Dec. 30 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that it has reduced the minimum tender condition and extended its previously announced tender offer to purchase all of the outstanding shares of common stock of Genelabs Technologies, Inc. (Nasdaq: GNLB), for $1.30 in cash per share without interest and less any required withholding taxes. The minimum tender condition was reduced to the number of Genelabs' shares that when added to the maximum...

2008-12-15 08:00:00

LONDON, Dec. 15 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that it has extended its previously announced tender offer to purchase all of the outstanding shares of common stock of Genelabs Technologies, Inc. (Nasdaq: GNLB), for $1.30 in cash per share without interest and less any required withholding taxes, until 5:00 p.m.New York City time on Monday, December 29, 2008, unless the tender offer is further extended. The tender offer was scheduled to expire at...

2008-12-08 08:11:00

LONDON, and PHILADELPHIA, Dec. 8 /PRNewswire-FirstCall/ -- GlaxoSmithKline (LSE/NYSE: GSK) announced today that it has extended its previously announced tender offer to purchase all of the outstanding shares of common stock of Genelabs Technologies, Inc. (Nasdaq: GNLB), for $1.30 in cash per share without interest and less any required withholding taxes, until 12:00 midnight EST on Friday, December 12, 2008, unless the tender offer is further extended. The tender offer was originally...

2008-12-03 15:30:00

LONDON and PHILADELPHIA, Dec. 3 /PRNewswire-FirstCall/ -- GlaxoSmithKline (LSE/NYSE: GSK) announced today that it is waiving a condition relating to a pending lawsuit in the previously announced tender offer to purchase all of the outstanding shares of common stock of Genelabs Technologies, Inc. (Nasdaq: GNLB), for $1.30 per share in cash without interest and less any required withholding taxes. It is a condition to the completion of the tender offer that there not be any pending or...

2008-10-22 09:00:42

GlaxoSmithKline Consumer Healthcare has reached an agreement with Laclede, a privately held company, to purchase the dry mouth brand Biotene for $170 million. The transaction is subject to regulatory review by competition authorities in the US and Europe, and is expected to complete by early 2009. John Clarke, president of GlaxoSmithKline consumer healthcare, said: "The acquisition of Biotene extends our portfolio in therapeutic oral healthcare to include a proven treatment for dry mouth....

2008-08-21 09:01:14

PHILADELPHIA, Aug. 21 /PRNewswire-FirstCall/ -- GlaxoSmithKline today announced that, beginning in February 2009, the company will proactively report educational and charitable grants provided to US health-related organizations. The report will be updated on a quarterly basis and will include grants provided to various organizations including hospitals, teaching institutions, managed care organizations, professional associations, patient advocacy groups, and continuing medical education...

2008-08-13 15:01:02

A wrongful death suit was filed against GlaxoSmithKline, SmithKline Beecham, and McKesson Corporation in California Superior Court, charging that Avandia, prescribed for Type 2 Diabetes, led to heart attacks, congestive heart failure and other fatal cardiovascular injuries in seven individuals. The suit, brought by Khorrami, Pollard & Abir and Kabateck Brown Kellner, LLP, was filed on behalf of the victims' seven surviving spouses, including Los Angeles, CA, and Costa Mesa, CA,...

2008-07-18 15:00:15

By Tom Fontaine, Beaver County Times, Pa. Jul. 18--MOON TWP. -- The pharmaceutical company GlaxoSmithKline will move its weight-loss and smoking-cessation national marketing groups from Moon Township to Parsippany, N.J., by the end of summer as part of a company reorganization. The two groups, which market brands such as Alli for weight loss and Nicoderm and Nicorette for smoking cessation, will "be managed under the single umbrella of a new unit that we will call behavioral sciences,"...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.